ClinicalTrials.gg
CompletedNCT03638258ARQ-151-201Updated Sep 2, 2022Results posted

The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

A Phase 2 interventional study of Roflumilast Cream 0.3% and Roflumilast Cream 0.15% in Plaque Psoriasis, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 30 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-02.

Sponsored by Arcutis Biotherapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
331
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing roflumilast in Psoriasis — 3 open to participants now, 3 under way, none of them phase 3. Roflumilast · Psoriasis.

Enrollment
6th of 17
331 · median 46
Started
2018
with 1 other
Phase 2
7 of 17
1 open now
Registered
3rd of 17
by date
Lead sponsor
9 of 17
Arcutis Biotherapeutics, Inc.

Among the 17 studies testing roflumilast in Psoriasis, this one is the 6th largest by enrollment, is one of 2 that started in 2018, is one of 7 in phase 2, and was the 3rd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

3 of the 17 studies testing roflumilast in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing roflumilast in Psoriasis, or all of them as a file.
02

Study summary

This is a parallel group, double blind, vehicle-controlled study in which roflumilast (ARQ-151) cream 0.3%, roflumilast cream 0.15%, or vehicle cream is applied once daily (QD) for 84 days to subjects with chronic plaque psoriasis involving between 2 and 20% body surface area.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants legally competent to sign and give
  • Males and females ages 18 years and older (inclusive)
  • Clinical diagnosis of psoriasis vulgaris of at least 6 months duration as determined by the Investigator
  • Females of (FOCBP) must have a negative urine pregnancy test at Screening (Visit 1) and Baseline (Visit 2). In addition, sexually active FOCBP must agree to use at least one form of highly effective throughout the trial.
  • In good health as judged by the Investigator, based on medical history, physical examination, serum chemistry labs, hematology values, and urinalysis.
  • Subjects are considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.

Exclusion criteria

Exclusion Criteria:

  • Planned excessive exposure of treated area(s) to either natural or artificial sunlight or tanning bed.
  • Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
  • Previous treatment with roflumilast cream or its active ingredient
  • Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.
  • Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of study medication.
  • Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
331 participants (actual)

Study arms

  • Experimental
    Roflumilast Cream 0.3%

    Roflumilast cream 0.3% topically applied QD for 12 weeks.

    Drug: Roflumilast Cream 0.3%

  • Experimental
    Roflumilast Cream 0.15%

    Roflumilast cream 0.15% topically applied QD for 12 weeks.

    Drug: Roflumilast Cream 0.15%

  • Placebo comparator
    Vehicle Cream

    Vehicle cream matched to roflumilast cream (containing only excipients of active cream) applied QD for 12 weeks.

    Drug: Vehicle Cream

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' at Week 6

    The percentage of participants with an IGA score of 0 ('clear') or 1 ('almost clear') at Week 6 is reported. The IGA is 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater plaque severity.

    Time frame: Week 6

Secondary outcomes

  1. Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear'

    The percentage of participants with an IGA score of 0 ('clear') or 1 ('almost clear') is reported. The IGA is 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater plaque severity.

    Time frame: Weeks 4, 8, and 12

  2. Change From Baseline in Modified Psoriasis Area Severity Index (mPASI) Score

    The percent change from baseline in mPASI score is presented. The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity. For scoring, the body is divided into four sections (head \[h\]: 10% of a person's skin; arms \[a\] 20%; trunk \[t\] 30%; legs (l\] 40%); for each section, the percent of area involved is estimated from 0 (0% involved) to 6 (90 to 100% involved). Then, within each area, the severity is estimated by three clinical signs: erythema ('E'; redness), induration ('T'; thickness), and desquamation ('S'; scaling). Severity parameters are measured on a scale of 0 to 4, from none to maximum severity possible. Each of these areas is scored by itself, and then the four scores are combined into the final mPASI, using the formula mPASI = 0.1 (Eh + Th + Sh) Ah + 0.2 (Ea + Ta + Sa) Aa + 0.3 (Et + Tt + St) At + 0.4 (El + Tl + Sl) Al.

    Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12

  3. Percent Change From Baseline in Body Surface Area (BSA) Affected

    The BSA affected by psoriasis was determined by the subject's hand method, where the subject's hand (including fingers) surface area was assumed to equal 1% of BSA. The mean percent change from baseline in BSA is presented.

    Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12

  4. Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' Plus a 2-Grade Improvement From Baseline

    The percentage of participants with an IGA score of 0 ('clear') or 1 ('almost clear') plus a 2-grade improvement from baseline is reported. The IGA is 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater plaque severity.

    Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12

  5. Percentage of Participants With an Intertriginous Area Investigator Global Assessment (I-IGA) Score of 'Clear' or 'Almost Clear' Who Had at Least Mild Lesions at Baseline

    The percentage of participants (who had intertriginous area involvement with an I-IGA score of at least mild at baseline) with at least a 2-grade improvement in I-IGA score at Weeks 4, 6, 8, and 12 is presented.

    Time frame: Weeks 4, 6, 8, and 12

  6. Change From Baseline in Worst Itch-Numeric Rating Scale (WI-NRS) Pruritus Score

    The WI-NRS is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours. The mean (SD) change in WI-NRS score from baseline is presented.

    Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12

  7. Percentage of Participants With Baseline Worst Itch-Numeric Rating Scale (WI-NRS) Pruritus Score ≥6 Who Experienced a 4-point Reduction

    The percentage of participants who had baseline WI-NRS scores ≥6 who achieved a 4-point reduction in WI-NRS score at Weeks 4, 6, 8, and 12 is reported. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours.

    Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12

  8. Percentage of Participants Achieving a Modified Psoriasis Area Severity Index-75 (mPASI-75) Compared to Baseline

    The percentage of subjects achieving a 75% reduction in mPASI (eg, mPASI-75) score relative to baseline is presented. The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity.

    Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12

  9. Percentage of Participants Achieving a Modified Psoriasis Area Severity Index-90 (mPASI-90) Compared to Baseline

    The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity. The percentage of subjects achieving a 90% reduction in mPASI (eg, mPASI-90) score relative to baseline is presented.

    Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12

  10. Change From Baseline in Psoriasis Symptom Diary (PSD) Total Score

    The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 11 ("worst imaginable symptoms"). Scores range from 0 to 176, with higher scores indicating greater symptom severity. The mean (SD) change in PSD total score relative to baseline is presented for each treatment arm.

    Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12

  11. Change From Baseline in Itch-Related Sleep Loss Numeric Rating Scale (NRS) Score

    The Itch-Related Sleep Loss NRS is a single item scale scored from 0 ("no itch-related sleep loss") to 10 ("itch-related sleep loss as bad as it could be") assessing the severity of itch-related sleep loss in the past 24 hours. The mean (SD) change from the baseline NRS score is presented for each treatment arm.

    Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12

  12. Change From Baseline in Dermatology Life Quality Index (DLQI) Score

    The DLQI is a 10-item scale asking subject to rate the severity of symptoms during the past week. Each item is scored from 0 ("not at all" or "not relevant") to 3 or 4 ("very much") \[2 questions are scored 0 to 3 and 8 questions are scored 0 to 4\]. The total DLQI score ranges from 0 to 48, with higher scores indicating greater symptom severity. The mean (SD) change from baseline DLQI score is presented.

    Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12

  13. Responses to Individual Questions of the Psoriasis Symptom Diary (PSD)

    Two items from the PSD asking participants to rate the overall severity of psoriasis-related itching and pain during the past 24 hours are presented. Each item is scored on an 11-point scale ranging from 0 ("no symptom") to 10 ("worst imaginable symptom"), with lower scores indicating lower symptoms severity. The mean (SD) score is presented for each treatment arm.

    Time frame: Weeks 4, 6, 8, and 12

07

Results

Posted Aug 10, 2022

Participant flow

Adult (≥18 years of age) male or female participants with chronic plaque psoriasis were recruited at 30 study sites in the US and Canada.

Participant flow — Overall Study
MilestoneRolumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle Cream
Started109113109
Completed10210486
Not completed7923
Withdrew: Adverse event102
Withdrew: Lost to follow-up245
Withdrew: Pregnancy001
Withdrew: Protocol violation001
Withdrew: Withdrawal by subject4512
Withdrew: Lack of efficacy002

Outcome measures

PrimaryPercentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' at Week 6

The percentage of participants with an IGA score of 0 ('clear') or 1 ('almost clear') at Week 6 is reported. The IGA is 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater plaque severity.

Time frame:
Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' at Week 6
percentage of participantsRoflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle Cream
Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' at Week 628.022.88.3
Statistical analysis
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = <0.001Logistic regression with a factor of treatment group and a covariate of baseline IGA score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Regression, Logistic · p = 0.004Logistic regression with a factor of treatment group and a covariate of baseline IGA score.
SecondaryPercentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear'

The percentage of participants with an IGA score of 0 ('clear') or 1 ('almost clear') is reported. The IGA is 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater plaque severity.

Time frame:
Weeks 4, 8, and 12
Reported as:
Number · percentage of participants
Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear'
percentage of participantsRoflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle Cream
Week 414.59.04.4
Week 837.930.611.9
Week 1237.532.116.3
Statistical analysis
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = 0.015Logistic regression with a factor of treatment group and a covariate of baseline IGA score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Regression, Logistic · p = 0.174Logistic regression with a factor of treatment group and a covariate of baseline IGA score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = <0.001Logistic regression with a factor of treatment group and a covariate of baseline IGA score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Regression, Logistic · p = 0.001Logistic regression with a factor of treatment group and a covariate of baseline IGA score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = <0.001Logistic regression with a factor of treatment group and a covariate of baseline IGA score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Regression, Logistic · p = 0.008Logistic regression with a factor of treatment group and a covariate of baseline IGA score.
SecondaryChange From Baseline in Modified Psoriasis Area Severity Index (mPASI) Score

The percent change from baseline in mPASI score is presented. The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity. For scoring, the body is divided into four sections (head \[h\]: 10% of a person's skin; arms \[a\] 20%; trunk \[t\] 30%; legs (l\] 40%); for each section, the percent of area involved is estimated from 0 (0% involved) to 6 (90 to 100% involved). Then, within each area, the severity is estimated by three clinical signs: erythema ('E'; redness), induration ('T'; thickness), and desquamation ('S'; scaling). Severity parameters are measured on a scale of 0 to 4, from none to maximum severity possible. Each of these areas is scored by itself, and then the four scores are combined into the final mPASI, using the formula mPASI = 0.1 (Eh + Th + Sh) Ah + 0.2 (Ea + Ta + Sa) Aa + 0.3 (Et + Tt + St) At + 0.4 (El + Tl + Sl) Al.

Time frame:
Baseline (Day 1) and Weeks 4, 6, 8, and 12
Reported as:
Mean · score on a scale
Change From Baseline in Modified Psoriasis Area Severity Index (mPASI) Score
score on a scaleRoflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle Cream
Week 4-40.08 ± 46.811-47.32 ± 29.717-18.01 ± 46.622
Week 6-53.15 ± 46.470-59.73 ± 32.409-16.42 ± 58.385
Week 8-59.09 ± 49.290-65.12 ± 31.97-18.47 ± 63.777
Week 12-59.48 ± 54.881-68.03 ± 33.021-13.65 ± 70.731
Statistical analysis
  • Roflumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline mPASI score.
  • Roflumilast Cream 0.15% · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline mPASI score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline mPASI score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline mPASI score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline mPASI score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · ANOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline mPASI score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline mPASI score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline mPASI score.
SecondaryPercent Change From Baseline in Body Surface Area (BSA) Affected

The BSA affected by psoriasis was determined by the subject's hand method, where the subject's hand (including fingers) surface area was assumed to equal 1% of BSA. The mean percent change from baseline in BSA is presented.

Time frame:
Baseline (Day 1) and Weeks 4, 6, 8, and 12
Reported as:
Mean · percentage of change
Percent Change From Baseline in Body Surface Area (BSA) Affected
percentage of changeRoflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle Cream
Week 4-21.74 ± 34.381-23.25 ± 27.084-5.33 ± 31.834
Week 6-34.88 ± 39.530-33.41 ± 32.136-8.19 ± 40.989
Week 8-41.58 ± 42.816-40.49 ± 34.379-7.40 ± 52.859
Week 12-48.56 ± 46.077-47.50 ± 36.304-6.74 ± 51.469
Statistical analysis
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline BSA score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Regression, Logistic · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline BSA score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline BSA score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline BSA score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline BSA score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline BSA score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline BSA score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline BSA score.
SecondaryPercentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' Plus a 2-Grade Improvement From Baseline

The percentage of participants with an IGA score of 0 ('clear') or 1 ('almost clear') plus a 2-grade improvement from baseline is reported. The IGA is 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater plaque severity.

Time frame:
Baseline (Day 1) and Weeks 4, 6, 8, and 12
Reported as:
Number · percentage of participants
Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' Plus a 2-Grade Improvement From Baseline
percentage of participantsRoflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle Cream
Week 410.06.94.4
Week 623.917.48.0
Week 832.224.59.8
Week 1231.327.413.6
Statistical analysis
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = 0.116Logistic regression with a factor of treatment group and a covariate of baseline IGA score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Regression, Logistic · p = 0.423Logistic regression with a factor of treatment group and a covariate of baseline IGA score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = 0.002Logistic regression with a factor of treatment group and a covariate of baseline IGA score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = 0.038Logistic regression with a factor of treatment group and a covariate of baseline IGA score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = <0.001Logistic regression with a factor of treatment group and a covariate of baseline IGA score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Regression, Logistic · p = 0.005Logistic regression with a factor of treatment group and a covariate of baseline IGA score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = 0.002Logistic regression with a factor of treatment group and a covariate of baseline IGA score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Regression, Logistic · p = 0.013Logistic regression with a factor of treatment group and a covariate of baseline IGA score.
SecondaryPercentage of Participants With an Intertriginous Area Investigator Global Assessment (I-IGA) Score of 'Clear' or 'Almost Clear' Who Had at Least Mild Lesions at Baseline

The percentage of participants (who had intertriginous area involvement with an I-IGA score of at least mild at baseline) with at least a 2-grade improvement in I-IGA score at Weeks 4, 6, 8, and 12 is presented.

Time frame:
Weeks 4, 6, 8, and 12
Reported as:
Number · percentage of participants
Percentage of Participants With an Intertriginous Area Investigator Global Assessment (I-IGA) Score of 'Clear' or 'Almost Clear' Who Had at Least Mild Lesions at Baseline
percentage of participantsRoflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle Cream
Week 446.643.817.6
Week 673.443.729.4
Week 887.160.936.1
Week 1294.332.424.3
Statistical analysis
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = 0.086Logistic regression with a factor of treatment group and a covariate of baseline I-IGA score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Regression, Logistic · p = 0.123Logistic regression with a factor of treatment group and a covariate of baseline I-IGA score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = 0.017Logistic regression with a factor of treatment group and a covariate of baseline I-IGA score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Regression, Logistic · p = 0.415Logistic regression with a factor of treatment group and a covariate of baseline I-IGA score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = 0.007Logistic regression with a factor of treatment group and a covariate of baseline I-IGA score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Regression, Linear · p = 0.175Logistic regression with a factor of treatment group and a covariate of baseline I-IGA score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = 0.001Logistic regression with a factor of treatment group and a covariate of baseline I-IGA score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Regression, Logistic · p = 0.619Logistic regression with a factor of treatment group and a covariate of baseline I-IGA score.
SecondaryChange From Baseline in Worst Itch-Numeric Rating Scale (WI-NRS) Pruritus Score

The WI-NRS is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours. The mean (SD) change in WI-NRS score from baseline is presented.

Time frame:
Baseline (Day 1) and Weeks 4, 6, 8, and 12
Reported as:
Mean · score on a scale
Change From Baseline in Worst Itch-Numeric Rating Scale (WI-NRS) Pruritus Score
score on a scaleRoflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle Cream
Week 4-2.8 ± 2.53-1.9 ± 2.45-1.1 ± 2.20
Week 6-3.3 ± 2.56-2.6 ± 2.73-1.3 ± 2.67
Week 8-3.5 ± 2.59-2.9 ± 2.73-1.5 ± 3.00
Week 12-3.4 ± 2.76-3.2 ± 2.84-1.3 ± 2.76
Statistical analysis
  • Roflumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline WI-NRS score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · ANCOVA · p = 0.002ANCOVA with a factor of treatment group and a covariate of baseline WI-NRS score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline WI-NRS score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline WI-NRS score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline WI-NRS score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline WI-NRS score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline WI-NRS score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline WI-NRS score.
SecondaryPercentage of Participants With Baseline Worst Itch-Numeric Rating Scale (WI-NRS) Pruritus Score ≥6 Who Experienced a 4-point Reduction

The percentage of participants who had baseline WI-NRS scores ≥6 who achieved a 4-point reduction in WI-NRS score at Weeks 4, 6, 8, and 12 is reported. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours.

Time frame:
Baseline (Day 1) and Weeks 4, 6, 8, and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Baseline Worst Itch-Numeric Rating Scale (WI-NRS) Pruritus Score ≥6 Who Experienced a 4-point Reduction
percentage of participantsRoflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle Cream
Week 450.935.424.9
Week 652.857.034.5
Week 864.658.242.3
Week 1262.870.132.9
Statistical analysis
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = 0.002Logistic regression with a factor of treatment group and a covariate of baseline WI-NRS score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · ANCOVA · p = 0.203ANCOVA with a factor of treatment group and a covariate of baseline WI-NRS score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = 0.034Logistic regression with a factor of treatment group and a covariate of baseline WI-NRS score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Regression, Logistic · p = 0.012Logistic regression with a factor of treatment group and a covariate of baseline WI-NRS score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = 0.010Logistic regression with a factor of treatment group and a covariate of baseline WI-NRS score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Regression, Logistic · p = 0.075Logistic regression with a factor of treatment group and a covariate of baseline WI-NRS score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = <0.001Logistic regression with a factor of treatment group and a covariate of baseline WI-NRS score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Regression, Logistic · p = <0.001Logistic regression with a factor of treatment group and a covariate of baseline WI-NRS score.
SecondaryPercentage of Participants Achieving a Modified Psoriasis Area Severity Index-75 (mPASI-75) Compared to Baseline

The percentage of subjects achieving a 75% reduction in mPASI (eg, mPASI-75) score relative to baseline is presented. The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity.

Time frame:
Baseline (Day 1) and Weeks 4, 6, 8, and 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Modified Psoriasis Area Severity Index-75 (mPASI-75) Compared to Baseline
percentage of participantsRoflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle Cream
Week 413.37.610.5
Week 624.122.29.6
Week 831.323.013.2
Week 1234.131.116.0
Statistical analysis
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = 0.527Logistic regression (Firth's penalized likelihood) with a factor of treatment group and a covariate of baseline PASI score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Regression, Logistic · p = 0.444Logistic regression (Firth's penalized likelihood) with a factor of treatment group and a covariate of baseline PASI score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = 0.006Logistic regression (Firth's penalized likelihood) with a factor of treatment group and a covariate of baseline PASI score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Regression, Logistic · p = 0.013Logistic regression (Firth's penalized likelihood) with a factor of treatment group and a covariate of baseline PASI score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = 0.002Logistic regression (Firth's penalized likelihood) with a factor of treatment group and a covariate of baseline PASI score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Regression, Logistic · p = 0.064Logistic regression (Firth's penalized likelihood) with a factor of treatment group and a covariate of baseline PASI score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = 0.002Logistic regression (Firth's penalized likelihood) with a factor of treatment group and a covariate of baseline PASI score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Regression, Logistic · p = 0.009Logistic regression (Firth's penalized likelihood) with a factor of treatment group and a covariate of baseline PASI score.
SecondaryPercentage of Participants Achieving a Modified Psoriasis Area Severity Index-90 (mPASI-90) Compared to Baseline

The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity. The percentage of subjects achieving a 90% reduction in mPASI (eg, mPASI-90) score relative to baseline is presented.

Time frame:
Baseline (Day 1) and Weeks 4, 6, 8, and 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Modified Psoriasis Area Severity Index-90 (mPASI-90) Compared to Baseline
percentage of participantsRoflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle Cream
Week 46.01.32.3
Week 614.32.33.2
Week 816.97.46.0
Week 1220.613.77.8
Statistical analysis
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = 0.188Logistic regression (Firth's penalized likelihood) with a factor of treatment group and a covariate of baseline PASI score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Regression, Logistic · p = 0.577Logistic regression (Firth's penalized likelihood) with a factor of treatment group and a covariate of baseline PASI score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = 0.008Logistic regression (Firth's penalized likelihood) with a factor of treatment group and a covariate of baseline PASI score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Regression, Logistic · p = 0.664Logistic regression (Firth's penalized likelihood) with a factor of treatment group and a covariate of baseline PASI score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = 0.015Logistic regression (Firth's penalized likelihood) with a factor of treatment group and a covariate of baseline PASI score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Regression, Logistic · p = 0.666Logistic regression (Firth's penalized likelihood) with a factor of treatment group and a covariate of baseline PASI score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · Regression, Logistic · p = 0.009Logistic regression (Firth's penalized likelihood) with a factor of treatment group and a covariate of baseline PASI score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · Regression, Logistic · p = 0.163Logistic regression (Firth's penalized likelihood) with a factor of treatment group and a covariate of baseline PASI score.
SecondaryChange From Baseline in Psoriasis Symptom Diary (PSD) Total Score

The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 11 ("worst imaginable symptoms"). Scores range from 0 to 176, with higher scores indicating greater symptom severity. The mean (SD) change in PSD total score relative to baseline is presented for each treatment arm.

Time frame:
Baseline (Day 1) and Weeks 4, 6, 8, and 12
Reported as:
Mean · percentage of participants
Change From Baseline in Psoriasis Symptom Diary (PSD) Total Score
percentage of participantsRoflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle Cream
Week 4-32.7 ± 34.61-32.7 ± 35.08-22.9 ± 31.85
Week 6-37.8 ± 35.71-38.0 ± 37.88-24.6 ± 38.15
Week 8-40.5 ± 36.62-40.1 ± 39.04-26.9 ± 41.78
Week 12-40.8 ± 41.12-43.4 ± 40.44-23.0 ± 41.38
Statistical analysis
  • Roflumilast Cream 0.3% vs Vehicle Cream · ANOVA · p = 0.002ANCOVA with a factor of treatment group and a covariate of baseline PSD score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · ANCOVA · p = 0.002ANCOVA with a factor of treatment group and a covariate of baseline PSD score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline PSD score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline PSD score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline PSD score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline PSD score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline PSD score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline PSD score.
SecondaryChange From Baseline in Itch-Related Sleep Loss Numeric Rating Scale (NRS) Score

The Itch-Related Sleep Loss NRS is a single item scale scored from 0 ("no itch-related sleep loss") to 10 ("itch-related sleep loss as bad as it could be") assessing the severity of itch-related sleep loss in the past 24 hours. The mean (SD) change from the baseline NRS score is presented for each treatment arm.

Time frame:
Baseline (Day 1) and Weeks 4, 6, 8, and 12
Reported as:
Mean · score on a scale
Change From Baseline in Itch-Related Sleep Loss Numeric Rating Scale (NRS) Score
score on a scaleRoflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle Cream
Week 4-1.1 ± 2.95-1.2 ± 2.54-1.0 ± 2.74
Week 6-1.5 ± 2.94-1.3 ± 2.65-0.9 ± 2.96
Week 8-1.6 ± 2.96-1.7 ± 2.75-0.9 ± 3.08
Week 12-1.8 ± 3.01-1.7 ± 2.66-1.1 ± 3.33
Statistical analysis
  • Roflumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = 0.184ANCOVA with a factor of treatment group and a covariate of baseline Itch-Related Sleep Loss score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · ANCOVA · p = 0.207ANCOVA with a factor of treatment group and a covariate of baseline Itch-Related Sleep Loss NRS score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = 0.004ANCOVA with a factor of treatment group and a covariate of baseline Itch-Related Sleep Loss NRS score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · ANCOVA · p = 0.022ANCOVA with a factor of treatment group and a covariate of baseline Itch-Related Sleep Loss NRS score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = 0.003ANCOVA with a factor of treatment group and a covariate of baseline Itch-Related Sleep Loss NRS score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · ANCOVA · p = <0.001ANCOVA with a factor of treatment group and a covariate of baseline Itch-Related Sleep Loss NRS score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = 0.003ANCOVA with a factor of treatment group and a covariate of baseline Itch-Related Sleep Loss NRS score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · ANCOVA · p = 0.01 (ANCOVA with a factor of treatment group and a covariate of baseline Itch-Related Sleep Loss NRS score.)
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) Score

The DLQI is a 10-item scale asking subject to rate the severity of symptoms during the past week. Each item is scored from 0 ("not at all" or "not relevant") to 3 or 4 ("very much") \[2 questions are scored 0 to 3 and 8 questions are scored 0 to 4\]. The total DLQI score ranges from 0 to 48, with higher scores indicating greater symptom severity. The mean (SD) change from baseline DLQI score is presented.

Time frame:
Baseline (Day 1) and Weeks 4, 6, 8, and 12
Reported as:
Mean · score on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Score
score on a scaleRoflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle Cream
Week 4-2.2 ± 3.46-2.3 ± 4.01-1.9 ± 4.29
Week 6-2.6 ± 3.64-3.1 ± 4.23-1.8 ± 4.23
Week 8-2.6 ± 3.68-3.5 ± 4.57-1.6 ± 4.77
Week 12-2.6 ± 4.48-4.2 ± 4.92-1.4 ± 5.28
Statistical analysis
  • Roflumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = 0.255ANCOVA with a factor of treatment group and a covariate of baseline DLQI score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · ANCOVA · p = 0.687ANCOVA with a factor of treatment group and a covariate of baseline DLQI score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = 0.045ANCOVA with a factor of treatment group and a covariate of baseline DLQI score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · ANCOVA · p = 0.059ANCOVA with a factor of treatment group and a covariate of baseline DLQI score.
  • Roflumilast Cream 0.3% · ANCOVA · p = 0.051ANCOVA with a factor of treatment group and a covariate of baseline DLQI score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · ANCOVA · p = 0.013ANCOVA with a factor of treatment group and a covariate of baseline DLQI score.
  • Roflumilast Cream 0.3% vs Vehicle Cream · ANCOVA · p = 0.036ANCOVA with a factor of treatment group and a covariate of baseline DLQI score.
  • Roflumilast Cream 0.15% vs Vehicle Cream · ANCOVA · p = 0.001ANCOVA with a factor of treatment group and a covariate of baseline DLQI score.
SecondaryResponses to Individual Questions of the Psoriasis Symptom Diary (PSD)

Two items from the PSD asking participants to rate the overall severity of psoriasis-related itching and pain during the past 24 hours are presented. Each item is scored on an 11-point scale ranging from 0 ("no symptom") to 10 ("worst imaginable symptom"), with lower scores indicating lower symptoms severity. The mean (SD) score is presented for each treatment arm.

Time frame:
Weeks 4, 6, 8, and 12
Reported as:
Mean · score on a scale
Responses to Individual Questions of the Psoriasis Symptom Diary (PSD)
score on a scaleRoflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle Cream
Week 4: Itching3.0 ± 2.873.3 ± 2.884.2 ± 3.02
Week 4: Pain1.8 ± 2.671.6 ± 2.462.6 ± 2.89
Week 6: Itching2.7 ± 2.702.8 ± 2.804.2 ± 2.96
Week 6: Pain1.5 ± 2.391.5 ± 2.522.3 ± 2.70
Week 8: Itching2.4 ± 2.702.4 ± 2.694.0 ± 2.92
Week 8: Pain1.3 ± 2.481.3 ± 2.362.4 ± 2.76
Week 12: Itching2.3 ± 2.782.2 ± 2.654.3 ± 3.14
Week 12: Pain1.2 ± 2.371.2 ± 2.352.5 ± 2.94

Adverse events

Collected over Up to 16 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roflumilast Cream 0.3%0/109 (0%)1/109 (0.9%)8/109 (7.3%)
Roflumilast Cream 0.15%0/113 (0%)1/110 (0.9%)7/110 (6.4%)
Vehicle Cream0/109 (0%)2/107 (1.9%)0/107 (0%)
Most frequent serious events
Most frequent serious events
EventRoflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle Cream
Basal ganglia infarctNervous system disorders0/1090/1101/107
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/1090/1101/107
Chest painCardiac disorders1/1090/1100/107
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1091/1100/107
Most frequent other events
Most frequent other events
EventRoflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle Cream
Upper respiratory tract infectionInfections and infestations8/1097/1100/107

Baseline characteristics

Age, Continuous
Age, Continuous(years)Roflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle CreamTotal
Mean51.7 ± 14.1154.4 ± 14.2055.5 ± 13.4953.9 ± 13.99
Sex: Female, Male
Sex: Female, Male(Participants)Roflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle CreamTotal
Female535142146
Male566267185
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Roflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle CreamTotal
Hispanic or Latino25262576
Not Hispanic or Latino848784255
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Roflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle CreamTotal
American Indian or Alaska Native0011
Asian87520
Native Hawaiian or Other Pacific Islander1210729
Black or African American0000
White829592269
More than one race71412
Unknown or Not Reported0000
Whole Body Investigator Global Assessment (IGA) Score
Whole Body Investigator Global Assessment (IGA) Score(Participants)Roflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle CreamTotal
0 - Clear0000
1 - Almost Clear0000
2 - Mild17181146
3 - Moderate848389256
4 - Severe812929
Intertriginous Area Investigator Global Assessment (I-IGA) Score
Intertriginous Area Investigator Global Assessment (I-IGA) Score(Participants)Roflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle CreamTotal
1 - Almost Clear1203
2 - Mild612725
3 - Moderate83819
4 - Severe1124
Itch-Related Sleep Loss Score
Itch-Related Sleep Loss Score(score on a scale)Roflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle CreamTotal
Mean2.9 ± 3.243.0 ± 3.193.4 ± 3.183.1 ± 3.20
Percentage of Body Surface Area (BSA) Affected
Percentage of Body Surface Area (BSA) Affected(percentage of body surface area)Roflumilast Cream 0.3%Roflumilast Cream 0.15%Vehicle CreamTotal
Mean6.33 ± 4.0056.44 ± 3.9156.43 ± 3.5976.40 ± 3.833

4 further baseline measures are reported on the registry.

08

Study locations

30 sites
  • Arcutis Clinical Site 35
    Beverly Hills, California 90212, United States
  • Arcutis Clinical Site 29
    Northridge, California 91324, United States
  • Arcutis Clinical Site 28
    San Diego, California 92123, United States
  • Arcutis Clinical Site 27
    Santa Monica, California 90403, United States
  • Arcutis Clinical Site 12
    Miami, Florida 33144, United States
  • Arcutis Clinical Site 16
    Sanford, Florida 32771, United States
  • Arcutis Clinical Site 21
    Louisville, Kentucky 40217, United States
  • Arcutis Clinical Site 34
    Clinton Township, Michigan 48038, United States
  • Arcutis Clinical Site 33
    Detroit, Michigan 48202, United States
  • Arcutis Clinical Site 20
    Fridley, Minnesota 55432, United States
  • Arcutis Clinical Site 22
    New York, New York 10029, United States
  • Arcutis Clinical Site 14
    High Point, North Carolina 27262, United States
  • Arcutis Clinical Site 39
    Bexley, Ohio 43209, United States
  • Arcutis Clinical Site 15
    Pittsburgh, Pennsylvania 15213, United States
  • Arcutis Clinical Site 19
    College Station, Texas 77845, United States
  • Arcutis Clinical Site 37
    Houston, Texas 77004, United States
  • Arcutis Clinical Site 13
    Houston, Texas 77056, United States
  • Arcutis Clinical Site 23
    San Antonio, Texas 78213, United States
  • Arcutis Clinical Site 24
    Webster, Texas 77598, United States
  • Arcutis Clinical Site 31
    Norfolk, Virginia 23502, United States
  • Arcutis Clinical Site 18
    Surrey, British Columbia V3R 6A7, Canada
  • Arcutis Clinical Site 11
    Surrey, British Columbia V3V 0C6, Canada
  • Arcutis Clinical Site 38
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Arcutis Clinical Site 10
    Ajax, Ontario L1S 7K8, Canada
  • Arcutis Clinical Site 25
    London, Ontario N6H 5L5, Canada
  • Arcutis Clinical Site 26
    Markham, Ontario L3P 1X2, Canada
  • Arcutis Clinical Site 32
    Oakville, Ontario L6J 7W5, Canada
  • Arcutis Clinical Site 17
    Peterborough, Ontario K9J 5K2, Canada
  • Arcutis Clinical Site 30
    Waterloo, Ontario N2J 1C4, Canada
  • Arcutis Clinical Site 36
    Windsor, Ontario N8W 1E6, Canada
09

References and documents

Publications

  • Stein Gold L, Alonso-Llamazares J, Draelos ZD, Gooderham MJ, Kempers SE, Kircik LH, Lebwohl MG, Papp KA, Pariser DM, Toth DP, Yosipovitch G, Higham RC, Feng A, Berk DR. Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial. Am J Clin Dermatol. 2023 Mar;24(2):305-313. doi: 10.1007/s40257-022-00739-3. Epub 2022 Nov 12. PubMed 36370336 ↗
  • Lebwohl MG, Papp KA, Stein Gold L, Gooderham MJ, Kircik LH, Draelos ZD, Kempers SE, Zirwas M, Smith K, Osborne DW, Trotman ML, Navale L, Merritt C, Berk DR, Welgus H; ARQ-151 201 Study Investigators. Trial of Roflumilast Cream for Chronic Plaque Psoriasis. N Engl J Med. 2020 Jul 16;383(3):229-239. doi: 10.1056/NEJMoa2000073. PubMed 32668113 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in May 2019, 8 months.

Results were first posted in Aug 2022, 3 years 2 months after primary completion. A results delay was requested in Aug 2020.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 8 months is below that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2018
First posted
Aug 20, 2018
StartActual
Sep 21, 2018
Primary completionActual
May 29, 2019
CompletionActual
May 29, 2019
Results delay requested
Aug 10, 2020
Results first posted
Aug 10, 2022
Last update
Sep 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03638258
Responsible party
Sponsor
First posted
Aug 20, 2018
Start date
Sep 21, 2018
Primary completion
May 29, 2019
Completion
May 29, 2019
Results posted
Aug 10, 2022
Last update
Sep 2, 2022

Study contacts

David Berk, MD
study director · Arcutis Biotherapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion